prosaposin N-glycosylated 6 (human)

A prosaposin (human) that has been N-glycosylated at the residue equivalent to Asn-101 of the amino acid sequence represented by UniProtKB:P07602-1, in which the glycan composition is represented by GlyTouCan:G27622TD. Example: UniProtKB:P07602-1, Asn-101, MOD:00160~GNO:G27622TD.


nuclear receptor coactivator 3 methylated 1 (human)

A nuclear receptor coactivator 3 (human) that has been methylated on the residue at the position equivalent to Arg-1163 of the amino acid sequence represented by UniProtKB:Q9Y6Q9-1. Example: UniProtKB:Q9Y6Q9-1, Arg-1163, MOD:00658.


urocanate hydratase isoform 1 (human)

A urocanate hydratase isoform 1 that is encoded in the genome of human.


urocanate hydratase isoform h2 (human)

A urocanate hydratase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96N76-2.


histone H2A type 2-B, initiator methionine removed asymmetrically-dimethylated 2 (human)

A histone H2A type 2-B (human) that has had the initiator methionine removed and has been post-translationally modified to include asymmetric dimethyl-L-arginine at position 12 of the amino acid sequence represented by UniProtKB:Q8IUE6. UniProtKB:Q8IUE6, 2-130, Arg-12, MOD:00077.


histone H2A type 2-A, initiator methionine removed dimethylated 1 (human)

A histone H2A type 2-A (human) that has had the initiator methionine removed and that has been dimethylated at the position equivalent to Arg-4 of the amino acid sequence represented by UniProtKB:Q6FI13. UniProtKB:Q6FI13, 2-130, Arg-4, MOD:00783.


Stage IIA Lung Small Cell Carcinoma AJCC v7

biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:NamedThing biolink:ThingWithTaxon

Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


neoplasm of thorax

A neoplasm (disease) that involves the thoracic segment of trunk.


Stage IVB Lung Cancer AJCC v8

Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


Advanced Bronchogenic Carcinoma

Bronchogenic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Lung squamous cell carcinoma stage I

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIA Lung Squamous Cell Carcinoma AJCC v7


Lung Adenocarcinoma by AJCC v7 Stage

A term that refers to the staging of lung adenocarcinoma, following the rules of the TNM AJCC v7 classification system.


Lung Secretory Carcinoma

A rare carcinoma that arises from the lung and has histopathological, immunohistochemical, and genetic features identical to those described in breast and salivary gland secretory carcinomas.


Stage IA Lung Small Cell Carcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Small cell lung cancer limited stage

Small cell lung carcinoma which is confined to one hemi-thorax and the regional lymph nodes.


neuroendocrine carcinoma of lung

A high grade malignant neoplasm that arises from the lung and is characterized by the presence of malignant neuroendocrine cells.  This category includes small cell lung carcinoma, large cell lung neuroendocrine carcinoma, and combined lung carcinoma.


Non-small cell lung cancer stage IIIB

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Metastatic non-small cell lung cancer

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Stage IIIA Lung Squamous Cell Carcinoma AJCC v7

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Cancer AJCC v8

Stage I includes: IA1: (T1mi, N0, M0); (T1a, N0, M0); IA2: (T1b, N0, M0); IA3: (T1c, N0, M0); IB: (T2a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Advanced Lung Adenosquamous Carcinoma

Lung adenosquamous carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Lung Micropapillary Adenocarcinoma

An aggressive variant of lung adenocarcinoma that exhibits a micropapillary architectural pattern. The prognosis is usually poor.


Invasive Lung Mucinous Adenocarcinoma

An invasive adenocarcinoma that arises from the lung. It is characterized by the presence of tall columnar cells and mucin production. This category refers to cases formerly classified as mucinous bronchioloalveolar carcinoma, excluding cases that meet the criteria for adenocarcinoma in situ or mucinous minimally invasive adenocarcinoma.


Lung Spindle Cell Carcinoma

A morphologic variant of sarcomatoid carcinoma characterized by the presence of malignant spindle cells and focal lymphoplasmacytic infiltrates.  Adenocarcinoma cells, malignant squamous cells, and giant cells are not present.


Locally Advanced Lung Non-Small Cell Carcinoma

A non-small cell carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage 0 Non-Small Cell Lung Cancer AJCC v6 and v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Occult Lung Cancer AJCC v8

Occult lung cancer includes: TX, N0, M0. TX: Primary tumor cannot be assessed. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Resectable Lung Adenocarcinoma

Lung adenocarcinoma that is amenable to surgical resection.


Advanced Lung Neuroendocrine Carcinoma

Lung neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Refractory Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma that is resistant to treatment.


Childhood Lung Small Cell Carcinoma

A rare small cell carcinoma of the lung that occurs during childhood.


Invasive Lung Non-Mucinous Adenocarcinoma

An invasive adenocarcinoma that arises from the lung. It is characterized by the absence of tall columnar cells and mucin production. This category includes lepidic adenocarcinoma, acinar adenocarcinoma, papillary adenocarcinoma, micropapillary adenocarcinoma, and solid adenocarcinoma.


Lung Small Cell Carcinoma, A Subtype

A molecular subtype of lung small cell carcinoma characterized by the overexpression of achaete-scute homolog 1 (ASCL1) transcription factor. It is associated with high expression of neuroendocrine markers and classic morphology.


Refractory Lung Non-Small Cell Squamous Carcinoma

Lung non-small cell squamous carcinoma that is resistant to treatment.


Lung Carcinoma Metastatic in the Brain

A carcinoma that has spread to the brain from its original site in the lung, through the hematogenous route.


Stage IIIC Lung Cancer AJCC v8

Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Advanced Lung Neuroendocrine Neoplasm

A lung neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


Metastatic Lung Small Cell Carcinoma

A small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Refractory Extensive Stage Lung Small Cell Carcinoma

Extensive stage small cell lung carcinoma that does not respond to treatment.


Stage 0 Squamous Cell Lung Carcinoma AJCC v6 and v7


Unresectable Lung Non-Small Cell Squamous Carcinoma

Lung non-small cell squamous carcinoma that is not amenable to surgical resection.


Non-small cell lung cancer stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Occult Lung Carcinoma

A lung carcinoma detectable by sputum cytology or bronchial washings only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Platinum-Resistant Lung Small Cell Carcinoma

Lung small cell carcinoma that is resistant to platinum therapy.


Lung Squamous Cell Carcinoma, Small Cell Variant

A poorly differentiated morphologic variant of squamous cell lung carcinoma characterized by the presence of small tumor cells with focal squamous differentiation.


Lung squamous cell carcinoma metastatic

A squamous cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Lung Non-Keratinizing Squamous Cell Carcinoma

A squamous cell lung carcinoma characterized by the absence of keratinization, pearl formation, and intercellular bridges.


Stage IIIB Lung Cancer AJCC v8

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Stage IA Lung Squamous Cell Carcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Solid Lung Adenocarcinoma

A morphologic variant of lung adenocarcinoma characterized by the presence of polygonal malignant cells forming sheets. Acinar, papillary, micropapillary, or lepidic growth patterns are absent.  If the tumor is 100 percent solid, intracellular mucin should be present in at least five tumor cells in each of two high-power fields and confirmed with mucin immunohistochemical stains. Tumors formerly classified as large cell carcinomas expressing pneumocyte immunohistochemical markers, even if intracellular mucin is absent, are now included in this category.


A morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of Clara cells and/or type II cells.


Locally Advanced Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IIB Non-Small Cell Lung Carcinoma AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Lung Cancer by AJCC v7 Stage

A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 7th edition.


Unresectable Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that is not amenable to surgical resection.


Stage IIIA Lung Cancer AJCC v8

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Myoepithelial carcinoma of lung

A very rare malignant lung tumor with myoepithelial differentiation.


Unresectable Lung Carcinoid Tumor

Lung carcinoid tumor that is not amenable to surgical resection.


Resectable Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that is amenable to surgical resection.


Occult Lung Adenosquamous Carcinoma

An adenosquamous lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Metastatic Lung Neuroendocrine Neoplasm

A neuroendocrine neoplasm that arises from the lung and has spread to another anatomic site.


Stage IIIB Lung Small Cell Carcinoma without Pleural Effusion AJCC v7

Stage IIIB small cell lung carcinoma that has not spread to the pleural fluid.


Epithelioid hemangioendothelioma of lung

A low-grade malignant blood vessel neoplasm arising from the lung.  It is characterized by the presence of epithelioid endothelial cells.  The neoplastic cells are arranged in cords and nests, which are embedded in a myxoid to hyalinized stroma.


Metastatic Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.


Lung Non-Small Cell Cancer by AJCC v7 Stage

A term that refers to the staging of non-small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


Stage IIIA Lung Cancer AJCC v7

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Metastatic Lung Neuroendocrine Carcinoma

Lung neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.


Advanced Lung Non-Small Cell Carcinoma

Lung non-small cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Resectable Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma that is amenable to surgical resection.


Metastatic Lung Carcinoma

A carcinoma that arises from the lung and has metastasized to another anatomic site.


Advanced Lung Non-Small Cell Squamous Carcinoma

Non-small cell squamous lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage IIIA Lung Small Cell Carcinoma AJCC v7


Lung Osteosarcoma

A rare extraskeletal osteosarcoma that arises from the lung parenchyma.


Unresectable Lung Adenocarcinoma

Lung adenocarcinoma that is not amenable to surgical resection.


Stage 0 Lung Adenocarcinoma AJCC v6 and v7

Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)


Stage IB Lung Adenocarcinoma AJCC v7

Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Locally Advanced Lung Adenosquamous Carcinoma

Lung adenosquamous carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IA1 Lung Cancer AJCC v8

Stage IA1 includes: IA1: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Stage IB Lung Squamous Cell Carcinoma AJCC v7


Lung Small Cell Carcinoma, N Subtype

A molecular subtype of lung small cell carcinoma characterized by the overexpression of neurogenic differentiation factor 1 (NEUROD1). It is associated with low expression of neuroendocrine markers and variant morphology.


Stage IVA Lung Cancer AJCC v8

Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)


Advanced Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Childhood Malignant Lung Neoplasm

A malignant neoplasm that involves the lungs during childhood.


Stage II Lung Small Cell Carcinoma AJCC v7

Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Stage III Lung Cancer AJCC v7

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Cancer AJCC v7

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Lung Plasmacytoma

A plasmacytoma that arises in the lung.


Hodgkin's lymphoma of lung

A rare Hodgkin lymphoma that arises in and is confined to the lung at the time of diagnosis.


Adenocarcinoma of lung stage IIIA

Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IIB Lung Cancer AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Stage IB Non-Small Cell Lung Carcinoma AJCC v7


Metastatic Lung Adenosquamous Carcinoma

An adenosquamous carcinoma that arises from the lung and has metastasized to another anatomic site.


Stage IB Lung Small Cell Carcinoma AJCC v7


Localized Lung Carcinoma

Lung carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Refractory Lung Small Cell Carcinoma

Small cell lung carcinoma that does not respond to treatment.


Stage I Lung Cancer AJCC v6

Stage I includes: IA: (TI, N0, M0) and IB: (T2, N0, M0).  TI: Tumor 3 cm or less in greatest dimension surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor with any of the following features of size or extent: More than 3cm in greatest dimension.  Involves main bronchus, 2cm or more distal to the carina.  Invades the visceral pleura.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 6th ed.)


Locally Advanced Lung Neuroendocrine Carcinoma

Lung neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IA3 Lung Cancer AJCC v8

Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Lung Small Cell Carcinoma Molecular Subtypes

A header term that refers to the molecular classification of lung small cell carcinoma according to the relative expression of four transcription factors: achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), yes-associated protein 1 (YAP1), and POU class 2 homeobox 3 (POU2F3).


Stage II Lung Cancer AJCC v8

Stage II includes: IIA: (T2b, N0, M0); IIB: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension.  T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


Unresectable Lung Carcinoma

Lung carcinoma that is not amenable to surgical resection.


Lung Hyalinizing Clear Cell Carcinoma

An extremely rare, low-grade carcinoma that arises endobronchially in the central airways. It is associated with the presence of EWSR1-ATF1 fusion gene and EWSR1-ATF1 fusion protein expression. It is composed of small to medium-sized malignant epithelial cells with clear and eosinophilic cytoplasm forming nests, cords, and trabeculae in a myxohyaline and fibrous stroma.


Stage IA Lung Non-Small Cell Carcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage III Lung Cancer AJCC v6

Stage III includes: IIIA (T1, N2, M0); (T2, N2, M0); (T3, N1,M0); (T3, N2, M0) or IIIB (Any T, N3, M0); (T4, Any N, M0).  N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension of the primary tumor.  N2: Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s).  N3: Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).  T1: Tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor has any of the following features of size or extent: more than 3 cm in greatest dimension; involves the main bronchus, 2 cm or more distal to the carina; invades the visceral pleura; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.  T3: Tumor (of any size) directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung.  T4: Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina; or separate tumor nodules in the same lobe; or tumor with a malignant pleural effusion.  M0: No distant metastasis. (AJCC 6th ed.)


Refractory Lung Carcinoma

Lung carcinoma that does not respond to treatment.


Metastatic Carcinoma in the Lung

The spread of a carcinoma to the lung. This may be from a primary lung carcinoma, or from a carcinoma at a distant anatomic site.


Transplant-Related Lung Carcinoma

A lung carcinoma that arises in a patient with a history of organ transplantation.


Lung Cancer by AJCC v8 Stage

A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)


Lung Malignant PEComa

A malignant lung tumor that arises from perivascular epithelioid cells (PECs).


Adenocarcinoma of lung, stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Lung Small Cell Carcinoma, Neuroendocrine-High Subtype

Lung small cell carcinoma characterized by high expression pattern of different neuroendocrine markers such as chromogranin A, synaptophysin, neural cell adhesion molecule 1, and gastrin-releasing peptide. It is associated with low numbers of infiltrating immune cells (immune desert phenotype).


Stage IIB Lung Cancer AJCC v8

Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)


Lung Small Cell Carcinoma by AJCC v7 Stage

A term that refers to the staging of small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


thoracic cancer

A primary or metastatic malignant neoplasm affecting the tissues of the thorax.


Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Colon Carcinoma Metastatic in the Lung

A carcinoma that originates from the colonic wall and has spread to the lungs.


Adenocarcinoma of lung, stage II

Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Advanced Lung Carcinoma

A lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage III Lung Small Cell Carcinoma AJCC v7


Stage IV Lung Cancer AJCC v6

Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis present. (AJCC 6th ed.)


Lung Squamous Cell Carcinoma In Situ

A preinvasive bronchial neoplastic lesion affecting the squamous epithelium. It is characterized by the absence of progression of maturation from base to luminal surface, basilar zone expansion with cellular crowding throughout the epithelium, absence of the intermediate zone, and surface flattening confined to the most superficial cells. The nuclear-to-cytoplasmic ratio is often high and variable, the chromatin is coarse and uneven, and mitotic figures are present through full thickness. The cell size may be markedly increased. Anisocytosis and pleomorphism may be present. (Adapted from WHO, 2015)


Stage IIA Lung Adenocarcinoma AJCC v7

Stage IIA includes: (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Minimally Invasive Lung Mucinous Adenocarcinoma

A morphologic variant of minimally invasive lung adenocarcinoma characterized by tall columnar cells and mucin production.


Metastatic Lung Adenocarcinoma

Lung adenocarcinoma that has spread from its original site of growth to another anatomic site.


Unresectable Lung Non-Squamous Non-Small Cell Carcinoma

Lung non-squamous non-small cell carcinoma that is not amenable to surgical resection.


Unresectable Lung Large Cell Neuroendocrine Carcinoma

Lung large cell neuroendocrine carcinoma that is not amenable to surgical resection.


Locally Advanced Lung Neuroendocrine Neoplasm

A lung neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.


Lung Small Cell Carcinoma Neuroendocrine Subtype

A header term that refers to the classification of lung small cell carcinoma based on the expression pattern of different neuroendocrine markers such as chromogranin A, synaptophysin, neural cell adhesion molecule 1, and gastrin-releasing peptide.


keratinizing squamous cell carcinoma of lung

A squamous cell lung carcinoma characterized by the presence of keratinization, pearl formation, and/or intercellular bridges.


Lung Enteric Adenocarcinoma

A well-differentiated adenocarcinoma located in the lung periphery. It resembles colorectal adenocarcinoma with acinar and/or cribriform architecture and papillotubular structures.


Stage IIIB Lung Small Cell Carcinoma AJCC v7

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Lung Melanoma

A rare malignant neoplasm that derives from melanocytes and arises from the lung in a patient with no history of previous melanoma and no evidence of melanoma in another site at the time of diagnosis.  It usually presents as a solitary lesion and the prognosis is poor.


Metastatic Lung Carcinoid Tumor

Lung carcinoid tumor that has spread from its original site of growth to another anatomic site.


Stage IV Lung Cancer AJCC v7

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Stage 0 Lung Cancer AJCC v8

Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Stage IV Lung Squamous Cell Carcinoma AJCC v7


Stage IIA Non-Small Cell Lung Carcinoma AJCC v7


Stage IB Lung Cancer AJCC v7

Stage IB includes: T2a, N0, M0.  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Locally Advanced Lung Carcinoma

A lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Small cell lung cancer extensive stage

Small cell lung carcinoma which has spread beyond one hemi-thorax and the regional lymph nodes.


Lung Squamous Cell Carcinoma, Papillary Variant

A morphologic variant of squamous cell lung carcinoma characterized by the presence of papillary structures.


Advanced Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Oligometastatic Lung Carcinoma

Lung carcinoma that has metastasized to a limited number of sites.


Extramedullary Disease in Plasma Cell Myeloma Involving the Lung

Infiltration of the lung by malignant (clonal) plasma cells in patients with history of multiple myeloma.


Stage IIB Lung Small Cell Carcinoma AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Lung Carcinoma Metastatic in the Liver

A carcinoma that originates from the lung and has spread to the liver.


Lung Squamous Cell Carcinoma by AJCC v7 Stage

A term that refers to the staging of squamous cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.


Advanced Lung Carcinoid Tumor

Lung carcinoid tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.


Platinum-Sensitive Lung Small Cell Carcinoma

Lung small cell carcinoma that is sensitive to platinum therapy.


Lepidic Predominant Adenocarcinoma

A lung adenocarcinoma characterized by the presence of mildly and moderately differentiated adenocarcinoma cells across the alveolar walls with at least one focus of invasive carcinoma measuring more than 5 mm in greatest dimension.


Stage IIA Lung Cancer AJCC v8

Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Basaloid squamous cell carcinoma of lung

A morphologic variant of squamous cell lung carcinoma characterized by nuclear palisading.


Stage IV Lung Cancer AJCC v8

Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)


Colorectal Carcinoma Metastatic in the Lung

A carcinoma that originates from the wall of the colon or rectum and has spread to the lungs.


Lung Small Cell Carcinoma, Y Subtype

A molecular subtype of lung small cell carcinoma characterized by the overexpression of yes-associated protein 1 (YAP1) transcription factor.


Locally Advanced Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma that has spread to nearly tissues or lymph nodes.


Stage IIIB Lung Squamous Cell Carcinoma AJCC v7

Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Pulmonary Artery Intimal Sarcoma

A sarcoma arising from the arterial intima of pulmonary arteries.


Advanced Lung Small Cell Carcinoma

Small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


Stage IB Lung Cancer AJCC v8

Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)


Refractory Lung Non-Small Cell Carcinoma

Non-small cell lung carcinoma that does not respond to treatment.


Lung Small Cell Carcinoma, Neuroendocrine-Low Subtype

Lung small cell carcinoma characterized by low expression pattern of different neuroendocrine markers such as chromogranin A, synaptophysin, neural cell adhesion molecule 1, and gastrin-releasing peptide. It is associated with increased numbers of infiltrating immune cells (immune oasis phenotype).


Lung squamous cell carcinoma stage II

Stage II includes: IIA (T2b, N0, M0); (T1a, N1, M0); (T1b, N1, M0); (T2a, N1, M0) and IIB (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Resectable Lung Carcinoma

Lung carcinoma that is amenable to surgical resection.


Unresectable Lung Neuroendocrine Neoplasm

A lung neuroendocrine neoplasm that is not amenable to surgical resection.


Childhood Lung Non-Small Cell Carcinoma

A rare non-small cell carcinoma of the lung that occurs during childhood.


Locally Advanced Lung Adenocarcinoma

Lung adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Stage IIB Lung Squamous Cell Carcinoma AJCC v7

Stage IIB includes: (T2b, N1, M0); (T3, N0, M0).  T2b: Lung cancer with a tumor size more than 5 cm but 7 cm or less in greatest dimension.  T3: Lung cancer with a tumor size more than 7 cm or one that directly invades any of the following: parietal pleural (PL3) chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus (less than 2 cm distal to the carina but without involvement of the carina); or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe. N0: No regional lymph node metastasis.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 7th ed.)


Prostate Carcinoma Metastatic in the Lung

A carcinoma that arises from the prostate gland and has spread to the lungs.


Lung Small Cell Carcinoma, I Subtype

A molecular subtype of lung small cell carcinoma characterized by the low expression of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3) transcription factor signatures and elevated inflammatory gene signature expression.


Refractory Lung Adenocarcinoma

Lung adenocarcinoma that is resistant to treatment.


Stage IA Lung Adenocarcinoma AJCC v7

Stage IA includes: (T1a, N0, M0); (T1b, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Lung Small Cell Carcinoma AJCC v7

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Occult Lung Non-Small Cell Carcinoma

A non-small cell lung carcinoma detectable by sputum cytology only.  The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.


Stage IIIB Lung Small Cell Carcinoma with Pleural Effusion AJCC v7

Stage IIIB small cell lung carcinoma that has spread to the pleural fluid.


Secondary malignant neoplasm of lung

The spread of a malignant neoplasm to the lung. This may be from a primary lung malignant neoplasm, or from a malignant neoplasm at a distant site.


Non-mucinous adenocarcinoma in situ of lung

Lung adenocarcinoma in situ characterized by the presence of type II pneumocyte and/or Clara cell differentiation. Almost all cases of lung adenocarcinoma in situ are non-mucinous.


Lung Mucinous Adenocarcinoma In Situ

A very rare lung adenocarcinoma in situ variant characterized by the presence of tall columnar cells with basal nuclei and abundant cytoplasmic mucin.


Adenocarcinoma of lung, stage IV

Stage IV includes: (Any T, Any N, M1a); (Any T, Any N, M1b).  M1a: Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion.  M1b: Distant metastasis. (AJCC 7th ed.)


Metastatic Lung Non-Small Cell Carcinoma

A non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Combined Lung Small Cell Carcinoma and Lung Adenocarcinoma

A lung carcinoma characterized by a combination of small cell carcinoma and adenocarcinoma.


Lung squamous cell carcinoma stage III

Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB (T1a, N3, M0); (T1b, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N3, M0); (T4, N2, M0); (T4, N3, M0).  T4: Lung cancer with a tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodule(s) in a different ipsilateral lobe.  N1: Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary lymph nodes, including involvement by direct extension.  N2: Lung cancer with metastasis to ipsilateral mediastinal and/or subcarinal lymph nodes.  N3: Lung cancer with metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Metastatic Lung Non-Small Cell Squamous Carcinoma

A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.


Unresectable Lung Neuroendocrine Carcinoma

Lung neuroendocrine carcinoma that is not amenable to surgical resection.


Locally Advanced Lung Non-Small Cell Squamous Carcinoma

A non-small cell squamous carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.


Lung Cancer by AJCC v6 Stage

A term that refers to the staging of lung carcinoma according to the American Joint Committee on Cancer, 6th edition.


Lung Carcinoma Metastatic in the Central Nervous System

A carcinoma that has spread to the central nervous system from its original site in the lung, through the hematogenous route.


Stage II Lung Cancer AJCC v6

Stage II includes: IIA (T1, N1, M0) and IIB (T2, N1, M0) or (T3, N0, M0).  T1: Tumor is 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, and without bronchoscopic evidence of invasion more proximal than the lobar bronchus.  T2: Tumor has any of the following features of size or extent: more than 3 cm in greatest dimension; involves the main bronchus, 2 cm or more distal to the carina; invades the visceral pleura; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung.  T3: Tumor (of any size) directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung. N0: No regional lymph node metastasis.  N1: Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension of the primary tumor. M0: No distant metastasis. (AJCC 6th ed.)


Stage IV Lung Small Cell Carcinoma AJCC v7


Refractory Lung Non-Squamous Non-Small Cell Carcinoma

Non-squamous non-small cell lung carcinoma that is resistant to treatment.


Lung Small Cell Carcinoma, P Subtype

A molecular subtype of lung small cell carcinoma characterized by the overexpression of POU class 2 homeobox 3 (POU2F3) transcription factor.


Stage III Lung Cancer AJCC v8

Stage III includes: IIIA: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); IIIB: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0); IIIC: (T3, N3, M0); (T4, N3, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)


Adenocarcinoma of lung, stage I

Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0) and IB: (T2a, N0, M0).  T1a: Lung cancer with a tumor size of 2 cm or less n greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). The uncommon superficial tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a.  T1b: Lung cancer with a tumor size more than 2 cm but 3 cm or less in greatest dimension, surrounded by lung or visceral pleura and without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus).  T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension.  N0: No regional lymph metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


carcinosarcoma of lung

A morphologic variant of lung sarcomatoid carcinoma composed of a mixture of non-small cell lung carcinoma and a sarcomatous component.


Lung Squamous Cell Carcinoma, Clear Cell Variant

A morphologic variant of squamous cell lung carcinoma characterized by the presence of clear cells.


constitutional neutropenia

A rare disorder characterized by recurrent infantile infections and absence of neutrophils in the peripheral blood.


lipoyl amidotransferase LIPT1, mitochondrial phosphorylated 1 (human)

A lipoyl amidotransferase LIPT1, mitochondrial (human) that has been phosphorylated on the residue at the position equivalent to Ser-191 of the amino acid sequence represented by UniProtKB:Q9Y234. UniProtKB:Q9Y234, Ser-191, MOD:00046.


ribonucleoside-diphosphate reductase large subunit isoform 1 (human)

A ribonucleoside-diphosphate reductase large subunit isoform 1 that is encoded in the genome of human.


ribonucleoside-diphosphate reductase large subunit methylated 2 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been methylated on the residue at the position equivalent to Cys-429 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-429, MOD:00660.


ribonucleoside-diphosphate reductase large subunit deaminated 2 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been deaminated on the residue at the position equivalent to Gln-530 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Gln-530, MOD:00685.


ribonucleoside-diphosphate reductase large subunit methylated 1 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been methylated on the residue at the position equivalent to Cys-26 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-26, MOD:00660.


ribonucleoside-diphosphate reductase large subunit cysteinylated 2 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been cysteinylated on the residue at the position equivalent to Cys-444 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-444, MOD:00765.


ribonucleoside-diphosphate reductase large subunit deaminated 1 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been deaminated on the residue at the position equivalent to Asn-85 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Asn-85, MOD:00684.


ribonucleoside-diphosphate reductase large subunit deaminated 3 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been deaminated on the residue at the position equivalent to Gln-678 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Gln-678, MOD:00685.


ribonucleoside-diphosphate reductase large subunit cysteinylated 1 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been cysteinylated on the residue at the position equivalent to Cys-26 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-26, MOD:00765.


ribonucleoside-diphosphate reductase large subunit cysteinylated 3 (human)

A ribonucleoside-diphosphate reductase large subunit (human) that has been cysteinylated on the residue at the position equivalent to Cys-429 of the amino acid sequence represented by UniProtKB:P23921. UniProtKB:P23921, Cys-429, MOD:00765.


histone-lysine N-methyltransferase NSD2 isoform h7 (human)

A histone-lysine N-methyltransferase NSD2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O96028-7.


serine/threonine-protein kinase 4 hydroxylated 1 (human)

A serine/threonine-protein kinase 4 (human) that has been hydroxylated on the residue at the position equivalent to Trp-99 of the amino acid sequence represented by UniProtKB:Q13043-1. Example: UniProtKB:Q13043-1, Trp-99, MOD:01622.


epicillin

A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido group.


azlocillin

A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.


phenoxymethylpenicillin

A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.


methicillin

A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.


flavocillin

A penicillin in which the substituent at position 6 of the penam ring is a [3-(4-oxo-4H-chromen-2-yl)benzoyl]nitrilo group.


sulbenicillin

A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.


Penicillanic acid carrying a (p-aminophenyl)imino]pentylidene}amino substituent at the 6beta position. It has been used as a hapten in the production of a generic monoclonal antibody for determining penicillin residues in milk.


pivmecillinam

A penicillanic acid ester that is the [(2,2-dimethylpropanoyl)oxy]methyl ester and prodrug of mecillinam.


mecillinam

A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.


metampicillin

A penicillin compound having a 6beta-(2R)-2-(methylideneamino)-2-phenylacetamido side-group.


temocillin

A penicillin compound having a 6alpha-methoxy and 6beta-[2-carboxy(thiophen-3-yl)acetamido side-groups.


penicillin O

A penicillin where the side-chain N-acyl group is specified as allylmercaptoacetyl. Antibiotic isolated from Penicillium chrysogenum.


phenethicillin

A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.


ticarcillin

A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.


quinacillin

A semisynthetic penicillase-resistant penicillin with antibacterial activity; it binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall.


N-benzoylampicillin

A penicillin that is the N-benzoyl derivative of ampicillin.


clometocillin

A penicillin that is benzylpenicillin in which the phenylacetyl group has been replaced by a (3,4-dichlorophenyl)(methoxy)acetyl group. It is a mixture of epimers at the methoxy-bearing carbon.


Penicillanic acid carrying a (p-hydroxybenzylidene)amino substituent at the 6beta position. It has been used as a hapten in the production of a generic monoclonal antibody for determining penicillin residues in milk.


penicillin allergen

Any penicillin which causes the onset of an allergic reaction.


mezlocillin

A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.


hyaluronan and proteoglycan link protein 1 isoform 1 (human)

A hyaluronan and proteoglycan link protein 1 isoform 1 that is encoded in the genome of human.


hyaluronan and proteoglycan link protein 1

A hyaluronan and proteoglycan link protein that is a translation product of the human HAPLN1 gene or a 1:1 ortholog thereof.


xylulose 5-phosphate

A xylulose phosphate in which the phosphate group is at position 5. It is an intermediate metabolite in the pentose phosphate pathway.


U5 small nuclear ribonucleoprotein 200 kDa helicase isoform 1 (human)

A U5 small nuclear ribonucleoprotein 200 kDa helicase isoform 1 that is encoded in the genome of human.


sodium/potassium/calcium exchanger 2 isoform h1 (human)

A sodium/potassium/calcium exchanger 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UI40-1.


mitogen-activated protein kinase 9 isoform hAlpha-2 (human)

A mitogen-activated protein kinase 9 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P45984-1.


mitogen-activated protein kinase 9 phosphorylated 1 (human)

A mitogen-activated protein kinase 9 (human) that has been phosphorylated on the residue at the position equivalent to Thr-183, and phosphotyrosine at position 185 of the amino acid sequence represented by UniProtKB:P45984. UniProtKB:P45984, Thr-183, MOD:00047|Tyr-185, MOD:00048.


mitogen-activated protein kinase 9 isoform hBeta-1 (human)

A mitogen-activated protein kinase 9 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P45984-3.


mitogen-activated protein kinase 9 isoform Alpha-1 (human)

A mitogen-activated protein kinase 9 isoform 2 that is encoded in the genome of human.


mitogen-activated protein kinase 9 isoform h5 (human)

A mitogen-activated protein kinase 9 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P45984-5.


mitogen-activated protein kinase 9 isoform hBeta-2 (human)

A mitogen-activated protein kinase 9 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P45984-4.


carbohydrate sulfotransferase 13 isoform h1 (human)

A carbohydrate sulfotransferase 13 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8NET6-1.


carbohydrate sulfotransferase 13

A protein that is a translation product of the human CHST13 gene or a 1:1 ortholog thereof.


carbohydrate sulfotransferase 13 isoform h2 (human)

A carbohydrate sulfotransferase 13 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8NET6-2.


voltage-gated potassium channel subunit KCNQ1 sequence variant R190Q (human)

A potassium voltage-gated channel subfamily KQT member 1 (human) that has a Gln residue at the position equivalent to Arg-190 of the amino acid sequence represented by UniProtKB:P51787-1. Example: UniProtKB:P51787-1, Arg-190, CHEBI:30011.


steroidogenic factor 1 acetylated 1 (human)

A steroidogenic factor 1 acetylated 1 in human. UniProtKB:Q13285, Lys-106/Lys-109/Lys-110, MOD:00064.


Colon Liposarcoma

A liposarcoma that arises from the colon.


calcium-dependent secretion activator 1 isoform h3 (human)

A calcium-dependent secretion activator 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9ULU8-3.


2-dodecenoic acid

A dodecenoic acid having its double bond at position 2.


dodecenoic acid

A C12, straight-chain fatty acid carrying a double bond at any position.


5-dodecenoic acid

A dodecenoic acid having its double bond in the 5-position.


prosaposin N-glycosylated 1 (human)

A prosaposin (human) that has been N-glycosylated at the residue equivalent to Asn-101 of the amino acid sequence represented by UniProtKB:P07602-1, in which the glycan composition is represented by GlyTouCan:G03930BU. Example: UniProtKB:P07602-1, Asn-101, MOD:00160~GNO:G03930BU.


serine/threonine-protein kinase 25 isoform h2 (human)

A serine/threonine-protein kinase 25 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O00506-2.


serine/threonine-protein kinase 25 isoform 1 (human)

A serine/threonine-protein kinase 25 isoform 1 that is encoded in the genome of human.


serine/threonine-protein kinase 25 isoform h3 (human)

A serine/threonine-protein kinase 25 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O00506-3.


alpha-L-rhamnopyranose

An L-rhamnopyranose having alpha-configuration at the anomeric centre.


serine-threonine kinase receptor-associated protein methylated 1 (human)

A serine-threonine kinase receptor-associated protein (human) that has been methylated on the residue at the position equivalent to Cys-270 of the amino acid sequence represented by UniProtKB:Q9Y3F4-1. Example: UniProtKB:Q9Y3F4-1, Cys-270, MOD:00660.


ephrin type-B receptor 1, signal peptide removed form (human)

An ephrin type-B receptor 1 (human) that has had the signal peptide removed. UniProtKB:P54762, 18-984.


ephrin type-B receptor 1, signal peptide removed phosphorylated 1 (human)

An ephrin type-B receptor 1 (human) that has had the signal peptide removed and has been post-translationally modified to include phosphotyrosine at positions 594 and 600 of the amino acid sequence represented by UniProtKB:P54762. UniProtKB:P54762, 18-984, Tyr-594/Tyr-600, MOD:00048.


alpha-N-acetylgalactosaminidase N-glycosylated 46 (human)

An alpha-N-acetylgalactosaminidase (human) that has been N-glycosylated at the residue equivalent to Asn-201 of the amino acid sequence represented by UniProtKB:P17050-1, in which the glycan structure is represented by GlyTouCan:G07617FP. Example: UniProtKB:P17050-1, Asn-201, MOD:00160~GNO:G07617FP.


transcription factor Sp1 isoform 1 phosphorylated 4 (human)

A transcription factor Sp1 isoform 1 phosphorylated 4 in human.


protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 isoform h2 (human)

A protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8WZA1-2.


maltase-glucoamylase O-glycosylated 1 (human)

A maltase-glucoamylase (human) that has been O-glycosylated at the residue equivalent to Thr-80 of the amino acid sequence represented by UniProtKB:O43451-1, in which the glycan composition is represented by GlyTouCan:G53434XO. Example: UniProtKB:O43451-1, Thr-80, MOD:00005~GNO:G53434XO.


amyloid-beta precursor protein sequence variant A692G (human)

An amyloid-beta precursor protein sequence variant (human) that has a Gly residue at the position equivalent to Ala-692 of the amino acid sequence represented by UniProtKB:P05067-1. Example: UniProtKB:P05067-1, Ala-692, CHEBI:29947.


adenosine deaminase 2 deaminated 4 (human)

An adenosine deaminase 2 (human) that has been deaminated on the residue at the position equivalent to Gln-474 of the amino acid sequence represented by UniProtKB:Q9NZK5-1. Example: UniProtKB:Q9NZK5-1, Gln-474, MOD:00685.


adenosine deaminase 2, signal peptide removed form (human)

An adenosine deaminase 2 (human) that has had the signal peptide removed. UniProtKB:Q9NZK5, 30-511.


adenosine deaminase 2 deaminated 3 (human)

An adenosine deaminase 2 (human) that has been deaminated on the residue at the position equivalent to Gln-274 of the amino acid sequence represented by UniProtKB:Q9NZK5-1. Example: UniProtKB:Q9NZK5-1, Gln-274, MOD:00685.


adenosine deaminase 2 deaminated 2 (human)

An adenosine deaminase 2 (human) that has been deaminated on the residue at the position equivalent to Asn-478 of the amino acid sequence represented by UniProtKB:Q9NZK5-1. Example: UniProtKB:Q9NZK5-1, Asn-478, MOD:00684.


adenosine deaminase 2 isoform h2 (human)

An adenosine deaminase 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NZK5-2.


adenosine deaminase 2 deaminated 1 (human)

An adenosine deaminase 2 (human) that has been deaminated on the residue at the position equivalent to Gln-270 of the amino acid sequence represented by UniProtKB:Q9NZK5-1. Example: UniProtKB:Q9NZK5-1, Gln-270, MOD:00685.


adenosine deaminase 2 isoform h1 (human)

An adenosine deaminase 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NZK5-1.


(S)-chlormezanone

The (S)-enantiomer of chlormezanone.


RAF proto-oncogene serine/threonine-protein kinase phosphotyrosine form (human)

A RAF proto-oncogene serine/threonine-protein kinase (human) that includes at least 1 phosphorylated tyrosine. UniProtKB:P04049, MOD:00048.


glutamate dehydrogenase 2, mitochondrial, transit peptide removed form (human)

A glutamate dehydrogenase 2, mitochondrial (human) that has had the transit peptide removed. UniProtKB:P49448, 54-558.


glutamate dehydrogenase 2, mitochondrial, transit peptide removed N6-acetyllysine form (human)

A glutamate dehydrogenase 2, mitochondrial (human) that has had the transit peptide removed and that includes at least 1 N6-acetyllysine. UniProtKB:P49448, 54-558, MOD:00064.


glutamate dehydrogenase 2, mitochondrial, transit peptide removed ADP-ribosylated form (human)

A glutamate dehydrogenase 2, mitochondrial (human) that has had the transit peptide removed and that includes at least 1 ADP-ribosylated residue. UniProtKB:P49448, 54-558, MOD:00752.


obg-like ATPase 1 methylated 2 (human)

An obg-like ATPase 1 (human) that has been methylated on the residue at the position equivalent to Cys-55 of the amino acid sequence represented by UniProtKB:Q9NTK5-1. Example: UniProtKB:Q9NTK5-1, Cys-55, MOD:00660.


obg-like ATPase 1 isoform h1 (human)

An obg-like ATPase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NTK5-1.


obg-like ATPase 1 isoform h2 (human)

An obg-like ATPase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NTK5-2.


obg-like ATPase 1 cysteinylated 1 (human)

An obg-like ATPase 1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-55 of the amino acid sequence represented by UniProtKB:Q9NTK5-1. Example: UniProtKB:Q9NTK5-1, Cys-55, MOD:00765.


obg-like ATPase 1 methylated 1 (human)

An obg-like ATPase 1 (human) that has been methylated on the residue at the position equivalent to Cys-117 of the amino acid sequence represented by UniProtKB:Q9NTK5-1. Example: UniProtKB:Q9NTK5-1, Cys-117, MOD:00660.


obg-like ATPase 1 isoform h3 (human)

An obg-like ATPase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NTK5-3.


obg-like ATPase 1 deaminated 1 (human)

An obg-like ATPase 1 (human) that has been deaminated on the residue at the position equivalent to Asn-215 of the amino acid sequence represented by UniProtKB:Q9NTK5-1. Example: UniProtKB:Q9NTK5-1, Asn-215, MOD:00684.


superoxide dismutase [Mn], mitochondrial, transit peptide removed acetylated 1 (human)

A superoxide dismutase [Mn], mitochondrial (human) that has had the transit peptide removed and that has been acetylated on the residue at the position equivalent to Lys-122 of the amino acid sequence represented by UniProtKB:P04179-1. Example: UniProtKB:P04179-1, 25-222, Lys-122, MOD:00064.


(R)-dimethenamid

A 2-chloro-N-(2,4-dimethylthiophen-3-yl)-N-[(2R)-1-methoxypropan-2-yl]acetamide that has R configuration. It is the inactive enantiomer; its (active) enantiomer is the herbicide known as dimethenamid-P; the racemate is the herbicide dimethenamid.


Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2

A protein that is a translation product of the human ASAP2 gene or a 1:1 ortholog thereof.


Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 isoform h1 (human)

An Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43150-1.


Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 isoform h2 (human)

An Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43150-2.


sodium/bile acid cotransporter 7 isoform 2 (human)

A sodium/bile acid cotransporter 7 isoform 2 that is encoded in the genome of human.


hexol

A polyol that contains 6 hydroxy groups.


thymidylate kinase isoform 1 (human)

A thymidylate kinase isoform 1 that is encoded in the genome of human.


endoplasmic reticulum aminopeptidase 1 hydroxylated 1 (human)

An endoplasmic reticulum aminopeptidase 1 (human) that has been hydroxylated on the residue at the position equivalent to Trp-932 of the amino acid sequence represented by UniProtKB:Q9NZ08-1. Example: UniProtKB:Q9NZ08-1, Trp-932, MOD:01622.


prolow-density lipoprotein receptor-related protein 1, signal peptide removed form (human)

A prolow-density lipoprotein receptor-related protein 1 (human) that has had the signal peptide removed. UniProtKB:Q07954, 20-4544.


very long chain fatty acid elongase 4 methylated 1 (human)

A very long chain fatty acid elongase 4 (human) that has been methylated on the residue at the position equivalent to Cys-163 of the amino acid sequence represented by UniProtKB:Q9GZR5. UniProtKB:Q9GZR5, Cys-163, MOD:00660.


apolipoprotein E citrullinated 1 (human)

An apolipoprotein E (human) that has been citrullinated on the residue at the position equivalent to Arg-199 of the amino acid sequence represented by UniProtKB:P02649. UniProtKB:P02649, Arg-199, MOD:00219.


mothers against decapentaplegic homolog 4 sequence variant W101* (human)

A mothers against decapentaplegic homolog 4 (human) that has has been truncated after the position equivalent to Arg-100 of the amino acid sequence represented by UniProtKB:Q13485. UniProtKB:Q13485, 1-100.


fibroblast growth factor receptor 1, signal peptide removed form (human)

A fibroblast growth factor receptor 1 (human) that has had the signal peptide removed. Example: UniProtKB:P11362-1, 22-822.


zinc finger transcription factor Trps1 isoform h1 (human)

A zinc finger transcription factor Trps1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UHF7-1.


E3 ubiquitin-protein ligase TRIM32, initiator methionine removed form (human)

An E3 ubiquitin-protein ligase TRIM32 (human) that has had the initiator methionine removed. UniProtKB:Q13049, 2-653.


[F-actin]-monooxygenase MICAL3 isoform h5 (human)

An [F-actin]-monooxygenase MICAL3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q7RTP6-5.


[F-actin]-monooxygenase MICAL3 isoform h2 (human)

An [F-actin]-monooxygenase MICAL3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q7RTP6-2.


[F-actin]-monooxygenase MICAL3 isoform h1 (human)

An [F-actin]-monooxygenase MICAL3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q7RTP6-1.


[F-actin]-monooxygenase MICAL3 phosphorylated 2 (human)

An [F-actin]-monooxygenase MICAL3 (human) that has been phosphorylated on the residue at the position equivalent to Ser-1649 of the amino acid sequence represented by UniProtKB:Q7RTP6-1. Example: UniProtKB:Q7RTP6-1, Ser-1649, MOD:00046.


[F-actin]-monooxygenase MICAL3 isoform h4 (human)

An [F-actin]-monooxygenase MICAL3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q7RTP6-4.


[F-actin]-monooxygenase MICAL3 isoform h3 (human)

An [F-actin]-monooxygenase MICAL3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q7RTP6-3.


[F-actin]-monooxygenase MICAL3 phosphorylated 1 (human)

An [F-actin]-monooxygenase MICAL3 (human) that has been phosphorylated on the residue at the position equivalent to Ser-1192 of the amino acid sequence represented by UniProtKB:Q7RTP6-1. Example: UniProtKB:Q7RTP6-1, Ser-1192, MOD:00046.


[F-actin]-monooxygenase MICAL3 methylated 1 (human)

An [F-actin]-monooxygenase MICAL3 (human) that has been methylated on the residue at the position equivalent to Cys-788 of the amino acid sequence represented by UniProtKB:Q7RTP6-1. Example: UniProtKB:Q7RTP6-1, Cys-788, MOD:00660.


[F-actin]-monooxygenase MICAL3 cysteinylated 1 (human)

An [F-actin]-monooxygenase MICAL3 (human) that has been cysteinylated on the residue at the position equivalent to Cys-788 of the amino acid sequence represented by UniProtKB:Q7RTP6-1. Example: UniProtKB:Q7RTP6-1, Cys-788, MOD:00765.


Echothiophate Iodide

The iodide salt of ecothiopate. An irreversible acetylcholinesterase inhibitor, it is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inadequate.


ornithine decarboxylase antizyme 3 isoform h1 (human)

An ornithine decarboxylase antizyme 3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UMX2-1.


ornithine decarboxylase antizyme 3 isoform h2 (human)

An ornithine decarboxylase antizyme 3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UMX2-2.


forkhead box protein K2 deaminated 1 (human)

A forkhead box protein K2 (human) that has been deaminated on the residue at the position equivalent to Gln-102 of the amino acid sequence represented by UniProtKB:Q01167-1. Example: UniProtKB:Q01167-1, Gln-102, MOD:00685.


apolipoprotein B-100 methylated 1 (human)

An apolipoprotein B-100 (human) that has been methylated on the residue at the position equivalent to Glu-1334 of the amino acid sequence represented by UniProtKB:P04114. UniProtKB:P04114, Glu-1334, MOD:00713.


zinc finger protein 64 isoform 2 (human)

A zinc finger protein 64 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NTW7-6.


L-dopachrome tautomerase isoform h2 (human)

An L-dopachrome tautomerase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P40126-2.


disabled homolog 2 deaminated 2 (human)

A disabled homolog 2 (human) that has been deaminated on the residue at the position equivalent to Asn-246 of the amino acid sequence represented by UniProtKB:P98082-1. Example: UniProtKB:P98082-1, Asn-246, MOD:00684.


glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2, initiator methionine removed form (human)

A glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 (human) that has had the initiator methionine removed. UniProtKB:O94808, 2-682.


glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2

A protein that is a translation product of the human GFPT2 gene or a 1:1 ortholog thereof.


glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 isoform 1 (human)

A glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 isoform 1 that is encoded in the genome of human.


glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 methylated 2 (human)

A glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 (human) that has been methylated on the residue at the position equivalent to Cys-461 of the amino acid sequence represented by UniProtKB:O94808. UniProtKB:O94808, Cys-461, MOD:00660.


glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 methylated 1 (human)

A glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 (human) that has been methylated on the residue at the position equivalent to Cys-375 of the amino acid sequence represented by UniProtKB:O94808. UniProtKB:O94808, Cys-375, MOD:00660.


plasminogen O-glycosylated 5 (human)

A plasminogen (human) that has been O-glycosylated at the residue equivalent to Ser-358 of the amino acid sequence represented by UniProtKB:P00747-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P00747-1, Ser-358, MOD:00002~GNO:G43417UB.


An oxysterol that is cholesterol which is substituted by a hydroxy group at position 24.


A 24-hydroxycholesterol that has R configuration at position 24.